Ziqi Li , Xiaoya Sun , Yanyu Zhao , Yuxin Ren , Hanqing Wu , Longbao Xu , Guoqing Li , Mengmeng Wang , Faming Pan
{"title":"基于生物信息学分析筛选强直性脊柱炎差异表达关键基因及其临床相关性研究","authors":"Ziqi Li , Xiaoya Sun , Yanyu Zhao , Yuxin Ren , Hanqing Wu , Longbao Xu , Guoqing Li , Mengmeng Wang , Faming Pan","doi":"10.1016/j.cca.2025.120411","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to identify potential biomarkers for Ankylosing Spondylitis (AS) through integrated bioinformatics analysis and case-control validation, thereby providing a theoretical basis for understanding the underlying pathogenesis of AS.</div></div><div><h3>Methods</h3><div>We first performed a comprehensive bioinformatics analysis integrated with a literature review to identify key candidate genes. Following this, a case-control validation study was carried out to verify the differential expression of these genes.</div></div><div><h3>Results</h3><div>Sixty-one differentially expressed genes (DEGs) were initially screened, and four key genes, ID2, PRF1, GZMB, and S100A12, were screened through comprehensive analysis and reference to relevant literature. Data from the qRT-PCR analysis indicated that the expression levels of ID2, PRF1, and GZMB were significantly reduced in patients with AS. The area under the ROC curve (AUC) indicated that among the single genes, ID2 had the best diagnostic performance, and the combined diagnostic performance of the four key genes was superior to that of ID2 alone. ID2 might regulate the apoptotic process of downstream PRF1 and GZMB through natural killer cells and CD8 cytotoxic T lymphocytes, thereby participating in the pathogenesis of AS. Furthermore, this study found that S100A12, PRF1 and GZMB were associated with multiple clinical indicators that reflected the level of inflammation or disease activity.</div></div><div><h3>Conclusions</h3><div>We identified four key DEGs via bioinformatics analysis and further validated them in case-control studies. The results indicated that these DEGs might serve as potential molecular targets for the diagnosis and treatment of AS.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120411"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Screening key genes differentially expressed in ankylosing spondylitis based on bioinformatics analysis and its clinical correlation study\",\"authors\":\"Ziqi Li , Xiaoya Sun , Yanyu Zhao , Yuxin Ren , Hanqing Wu , Longbao Xu , Guoqing Li , Mengmeng Wang , Faming Pan\",\"doi\":\"10.1016/j.cca.2025.120411\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>This study aimed to identify potential biomarkers for Ankylosing Spondylitis (AS) through integrated bioinformatics analysis and case-control validation, thereby providing a theoretical basis for understanding the underlying pathogenesis of AS.</div></div><div><h3>Methods</h3><div>We first performed a comprehensive bioinformatics analysis integrated with a literature review to identify key candidate genes. Following this, a case-control validation study was carried out to verify the differential expression of these genes.</div></div><div><h3>Results</h3><div>Sixty-one differentially expressed genes (DEGs) were initially screened, and four key genes, ID2, PRF1, GZMB, and S100A12, were screened through comprehensive analysis and reference to relevant literature. Data from the qRT-PCR analysis indicated that the expression levels of ID2, PRF1, and GZMB were significantly reduced in patients with AS. The area under the ROC curve (AUC) indicated that among the single genes, ID2 had the best diagnostic performance, and the combined diagnostic performance of the four key genes was superior to that of ID2 alone. ID2 might regulate the apoptotic process of downstream PRF1 and GZMB through natural killer cells and CD8 cytotoxic T lymphocytes, thereby participating in the pathogenesis of AS. Furthermore, this study found that S100A12, PRF1 and GZMB were associated with multiple clinical indicators that reflected the level of inflammation or disease activity.</div></div><div><h3>Conclusions</h3><div>We identified four key DEGs via bioinformatics analysis and further validated them in case-control studies. The results indicated that these DEGs might serve as potential molecular targets for the diagnosis and treatment of AS.</div></div>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":\"576 \",\"pages\":\"Article 120411\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0009898125002906\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125002906","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
Screening key genes differentially expressed in ankylosing spondylitis based on bioinformatics analysis and its clinical correlation study
Objective
This study aimed to identify potential biomarkers for Ankylosing Spondylitis (AS) through integrated bioinformatics analysis and case-control validation, thereby providing a theoretical basis for understanding the underlying pathogenesis of AS.
Methods
We first performed a comprehensive bioinformatics analysis integrated with a literature review to identify key candidate genes. Following this, a case-control validation study was carried out to verify the differential expression of these genes.
Results
Sixty-one differentially expressed genes (DEGs) were initially screened, and four key genes, ID2, PRF1, GZMB, and S100A12, were screened through comprehensive analysis and reference to relevant literature. Data from the qRT-PCR analysis indicated that the expression levels of ID2, PRF1, and GZMB were significantly reduced in patients with AS. The area under the ROC curve (AUC) indicated that among the single genes, ID2 had the best diagnostic performance, and the combined diagnostic performance of the four key genes was superior to that of ID2 alone. ID2 might regulate the apoptotic process of downstream PRF1 and GZMB through natural killer cells and CD8 cytotoxic T lymphocytes, thereby participating in the pathogenesis of AS. Furthermore, this study found that S100A12, PRF1 and GZMB were associated with multiple clinical indicators that reflected the level of inflammation or disease activity.
Conclusions
We identified four key DEGs via bioinformatics analysis and further validated them in case-control studies. The results indicated that these DEGs might serve as potential molecular targets for the diagnosis and treatment of AS.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.